As Covid-19 shifts the world's attention to biotech, Noubar Afeyan's Flagship builds $3.4B fund to fuel new inventions. Here's the plan
A little more than a year ago, Flagship Pioneering rolled out a monster fund with $1.1 billion in it to bankroll the platform companies they were creating inside their own labs. But it turns out, that was just the prelude to a much, much larger raise, as both current investors — who’ve been reaping the rewards of some booming biotech stocks — join in with new investors betting on more in the years to come.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.